Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Syndax Pharmaceuticals Inc (SNDX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update – Announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD – – Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the third quarter of 2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET –"
05/08/2023 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update – Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD on track for mid-2023 – – Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the third quarter of 2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET –"
02/28/2023 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update – Topline data from AUGMENT-101 KMT2Ar patients expected in the third quarter of 2023 – – Topline data from the pivotal AGAVE-201 trial on track for mid-2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET –"
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update - Enrollment remains on track for pivotal programs of SNDX-5613 and axatilimab; topline data expected starting in the first half of 2023 -",
"Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer"
11/15/2021 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update – Initiated pivotal Phase 2 portion of SNDX-5613 AUGMENT-101 trial in patients with NPM1 and MLLr acute leukemias –"
05/11/2021 8-K Quarterly results
11/02/2020 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update - Presentation of Phase 1 data from AUGMENT-101 trial of SNDX-5613 and initiation of Phase 2 on track for early 2021 -"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/03/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update – E2112 trial passed final interim OS analysis; trial continues, with final OS analysis expected in 2Q20 –"
08/07/2019 8-K Quarterly results
05/06/2019 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update – E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19 –"
03/07/2019 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update - Next interim OS assessment for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19 -"
11/05/2018 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update – Next assessment of primary endpoint of overall survival in E2112 trial expected in the second quarter of 2019 –"
08/07/2018 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update – PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expected in 3Q18 –"
05/08/2018 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update – PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expected in 3Q18 –"
03/05/2018 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update - Phase 2 ENCORE 601 PD-1 refractory melanoma cohort data and melanoma registration strategy disclosure forthcoming in 2Q18 -"
11/07/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update"
08/10/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 10, 2017 SYNDAX PHARMACEUTICALS, INC. Delaware 001-37708 32-0162505 Building D, Floor 3 35 Gatehouse Drive Waltham, Massachusetts 02451 Registrant's telephone number, including area code: 419-1400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ...",
"Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update"
05/08/2017 8-K Form 8-K - Current report
03/02/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
08/09/2016 8-K Quarterly results
Docs: "Pipeline Updates"
05/16/2016 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy